1. Home
  2. FFIN vs MIRM Comparison

FFIN vs MIRM Comparison

Compare FFIN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Financial Bankshares Inc.

FFIN

First Financial Bankshares Inc.

HOLD

Current Price

$33.31

Market Cap

4.7B

Sector

Finance

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$104.52

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FFIN
MIRM
Founded
1890
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
4.2B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
FFIN
MIRM
Price
$33.31
$104.52
Analyst Decision
Hold
Strong Buy
Analyst Count
2
12
Target Price
$37.50
$104.92
AVG Volume (30 Days)
711.4K
594.6K
Earning Date
04-24-2026
04-03-2026
Dividend Yield
2.28%
N/A
EPS Growth
12.23
53.75
EPS
1.26
N/A
Revenue
N/A
$19,138,000.00
Revenue This Year
$16.90
$55.91
Revenue Next Year
$6.41
$23.97
P/E Ratio
$26.45
N/A
Revenue Growth
N/A
N/A
52 Week Low
$29.44
$36.88
52 Week High
$38.74
$107.41

Technical Indicators

Market Signals
Indicator
FFIN
MIRM
Relative Strength Index (RSI) 51.52 68.04
Support Level $33.04 $98.70
Resistance Level $34.04 $107.41
Average True Range (ATR) 1.02 3.35
MACD -0.13 -0.46
Stochastic Oscillator 41.39 75.10

Price Performance

Historical Comparison
FFIN
MIRM

About FFIN First Financial Bankshares Inc.

First Financial Bankshares Inc is a financial and bank holding company. The company operates one line of business (community banking) located in a single geographic area (Texas). The company conducts a full-service commercial banking business through its subsidiaries. The loan portfolio segments of the company include Commercial and Industrial, Municipal, Agricultural, Construction and Development, Farm, Non-Owner Occupied and Owner Occupied Commercial Real Estate, Residential, Consumer Auto and Consumer Non-Auto. It derives maximum revenue from Construction and Development Segment.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: